Market Overview

Stifel Nicolaus Downgrades InterMune To Hold

Related ITMN
What You Need to Know About the Roche-InterMune Deal
Markets Reverse Early Morning Losses; Still Lower On The Day

Analysts at Stifel Nicolaus downgraded InterMune (NASDAQ: ITMN) from Buy to Hold and removed the price target of

InterMune shares have surged 262.29% over the past 52 weeks, while the S&P 500 index has gained 20.02% in the same period.

InterMune's shares surged 35.82% to $73.07 in pre-market trading.

Latest Ratings for ITMN

Aug 2014UBSDowngradesBuyNeutral
Aug 2014Cowen & Co.Initiates Coverage onMarket Perform
Aug 2014JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for ITMN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausDowngrades Analyst Ratings


Related Articles (ITMN)

View Comments and Join the Discussion!